Hormonal link to obesity may save lives

October 20, 2006

Saving the lives of overweight and obese people is the focus of research being conducted by a team of Brisbane-based researchers.

Dr Clair Sullivan from the Centre for Diabetes and Endocrine Research at the University of Queensland and Princess Alexandra Hospital, has been awarded a $55,000 Pfizer Australia Cardio Vascular Lipid (CVL) Research Grant to explore the likelihood of increasing life expectancy for obese and overweight people.

The aim of Dr Sullivan's work is understanding the link between obesity and cardiovascular disease.

While it is well documented that high cholesterol and high blood pressure in overweight people leads to cardiovascular disease, Dr Sullivan believes there is more putting these peoples' lives at risk.

"The high blood pressure and high cholesterol don't fully account for the increased risk of cardiovasular disease in obese people," Dr Sullivan said.

"Fat was once thought to be a storage organ but in fact it is an active organ which secretes many hormones."

"That could be one of the reasons why people who carry extra weight have an increased risk of getting cardiovascular disease."

Dr Sullivan's research is looking particularly at the role the hormones produced from fat are playing in causing blockages in the main heart arteries.

"It's exciting because we can hopefully reduce the cardiovascular risks for overweight and obese people."

The Pfizer Australia CVL Research Grants were established in 1999 to support clinical research into cardiovascular disease or related therapeutic areas.

They are open to Australian medical graduates who have entered the field of research (or who have returned after an appropriate break) within the last five years.

Funding for the CVL Research Grants will be up to $55,000. Each grant is for 12 months.

Pfizer Australia will allocate $1 million per annum to this initiative as part of their continued commitment to cardiovascular research in Australia.
-end-
Pfizer Australia is the nation's leading research-based health care company. It discovers, develops, manufactures and markets innovative medical treatments for both humans and animals. Pfizer Australia is investing more than $45 million in local research and development. For more information visit www.pfizer.com.au

MEDIA CONTACTS
Dr Clair Sullivan, University of Queensland. Catherine Bourgeois, Pfizer Australia Clinical Research Manager - Cardiovascular on 02 9850 3202 Adrian Dolahenty, Pfizer Australia Media Affairs on (0438) 656 175

Research Australia

Related Cardiovascular Disease Articles from Brightsurf:

Changes by income level in cardiovascular disease in US
Researchers examined changes in how common cardiovascular disease was in the highest-income earners compared with the rest of the population in the United States between 1999 and 2016.

Fighting cardiovascular disease with acne drug
Researchers from the European Molecular Biology Laboratory (EMBL) in Heidelberg and Stanford University have found the cause of dilated cardiomyopathy - a leading cause of heart failure - and identified a potential treatment for it: a drug already used to treat acne.

A talk with your GP may prevent cardiovascular disease
Having a general practitioner (GP) who is trained in motivational interviewing may reduce your risk of getting cardiovascular disease.

Dilemma of COVID-19, aging and cardiovascular disease
Whether individuals should continue to take angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the context of coronavirus disease 2019 (COVID-19) is discussed in this article.

Air pollution linked to dementia and cardiovascular disease
People continuously exposed to air pollution are at increased risk of dementia, especially if they also suffer from cardiovascular diseases, according to a study at Karolinska Institutet in Sweden published in the journal JAMA Neurology.

New insights into the effect of aging on cardiovascular disease
Aging adults are more likely to have - and die from - cardiovascular disease than their younger counterparts.

Premature death from cardiovascular disease
National data were used to examine changes from 2000 to 2015 in premature death (ages 25 to 64) from cardiovascular disease in the United States.

Ultrasound: The potential power for cardiovascular disease therapy
In the current issue of Cardiovascular Innovations and Applications volume 4, issue 2, pp.

Despite the ACA, millions of Americans with cardiovascular disease still can't get care
Cardiovascular disease (CVD) is the leading cause of death for Americans, yet millions with CVD or cardiovascular risk factors (CVRF) still can't access the care they need, even years after the implementation of the Affordable Care Act (ACA).

Excess weight and body fat cause cardiovascular disease
In the first Mendelian randomization study to look at this, researchers have found evidence that excess weight and body fat cause a range of heart and blood vessel diseases (rather than just being associated with it).

Read More: Cardiovascular Disease News and Cardiovascular Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.